Lodo Therapeutics

Curated by Signal

Developer novel therapeutics to treat resistant infectious diseases and cancers using AI

Life Sciences Technologylodotherapeutics.com

Overview

Developer novel therapeutics to treat resistant infectious diseases and cancers using AI. The company is focused on the discovery, biosynthesis, and characterization of new, genetically encoded small molecules from microbial sources. The company's metagenomics-driven discovery platform is used for the identification of microbiome-based pharmaceutical products derived. It also offers products against tuberculosis.

Key facts

Founded: 2015
Headquarters: New York City, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Contact

Primary office: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Ocean Genomics
Developer of a transcriptome analysis platform using AI
Life Sciences TechnologyPittsburgh, United States
BabyPlus
Auditory enrichment software
Life Sciences TechnologyFishers, United States
NX PharmaGen
Diagnostic technology for detection of circulating exosomes.
Life Sciences TechnologyLouisville, United States

About Lodo Therapeutics

What does Lodo Therapeutics do?

Developer novel therapeutics to treat resistant infectious diseases and cancers using AI.

Where is Lodo Therapeutics headquartered?

Lodo Therapeutics is headquartered in New York City, United States.

When was Lodo Therapeutics founded?

Lodo Therapeutics was founded in 2015.

Which sector is Lodo Therapeutics in?

Lodo Therapeutics operates in Life Sciences Technology.

Who are Lodo Therapeutics's competitors?

Companies similar to Lodo Therapeutics include Ocean Genomics, BabyPlus, and NX PharmaGen.